Bill > HR2376

This bill directs the Federal Trade Commission (FTC) to study the role of intermediaries, such as pharmacy benefit managers (PBMs), in the pharmaceutical supply chain. The FTC is required to report to Congress on whether PBMs engage in certain anticompetitive practices, such as charging payers higher prices than they reimburse pharmacies, steering patients to pharmacies in which the PBM has an ownership interest, or using formulary designs to increase the market share of higher-cost drugs. The bill also asks the FTC to identify any legal or regulatory obstacles it currently faces in ensuring a competitive and transparent marketplace in the pharmaceutical supply chain, and to provide policy or legislative recommendations to improve transparency and competition, prevent anticompetitive behavior, and ensure consumers benefit from any cost savings or efficiencies resulting from mergers and consolidations in the industry.

Business and Industry, Health and Social Services

https://www.congress.gov/bill/116th-congress/house-bill/2376/all-info